FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
Even with the coming of a new drug reimbursement environment that emphasizes profound innovation, don't expect to see the end of incremental biopharma innovation just yet.
The decision by Angelina Jolie to undergo a double mastectomy after tests determined she carried a genetic mutation that elevated her chances of developing breast or ovarian cancer has led to renewed calls for expanded genetic screening. It has also raised a disconcerting question-could genetic testing actually be harmful to your health?
As drug companies take divergent strategies focused either on research or cutting costs, what might this mean for the path future companies take in the pharmaceutical industry?
High-profile technology companies are revered by society while pharmaceutical companies developing life-saving technologies are viewed with contempt; why the disparity?
The tragic deaths of 55 Americans and sickening of more than 740, resulting from contaminated steroid injections that were shipped by a disreputable firm in Massachusetts, have rightly focused public attention on a largely unfamiliar, but prominent part of our drug supply chain – the practice of pharmacy compounding.
The enormous energy and possibility found in Silicon Valley should be harnessed in the most pressing work of developing entirely new therapies and technologies to answer healthcare's most complex questions.
Scott Gottlieb's testimony for the House Energy and Commerce Committee, Subcommittee on Health's hearing on drug compounding.
Drug companies -- at least every one that I've worked with -- would like to develop important new medicines that improve health and save lives. That's what gets every industry researcher I know up in the morning, and what keeps them going through the many highs and lows that characterize the scientific process.
Join New York Times columnist David Brooks as he engages the authors of “Brainwashed: The Seductive Appeal of Mindless Neuroscience” Sally Satel and Scott Lilienfeld, in a discussion of popular neuroscience.
Please join us for a preview of the revised and updated edition of Jonathan Nuechterlein and Philip Weiser’s influential 2005 book “Digital Crossroads: Telecommunications Law and Policy in the Internet Age” (MIT Press).
At this event, three expert panelists will examine this relationship from the perspectives of influential philosophers such as Aristotle, Alexis de Tocqueville, and representatives of the Scottish Enlightenment.
This event has been canceled. We apologize for any inconvenience.
At this event, Bennett and Wilezol will present their book, higher education finance experts Richard George and Richard Vedder will provide discussion, and a coffee reception and book signing will follow.
Join General Michael Hayden (ret.), AEI’s Marc Thiessen, and other leading experts in national security for a panel discussion on the significance of the NSA leaks.
Please join us for an event celebrating the release of Glenn Hubbard and Tim Kane’s “Balance: The Economics of Great Powers from Ancient Rome to Modern America” (Simon & Schuster, May 2013).
In light of the emerging Internal Revenue Service scandal, Senator McConnell will again join AEI to comment on the use of government power to stifle speech and will propose solutions that protect the individual rights that are guaranteed to all citizens of the United States.